Pfizer (NYSE:PFE) reported Phase 2b results for its GLP-1 anti-obesity candidate, PF-08653944, showing potential for a once ...

NVO and PFE clash as the obesity market heats up, with shifting strategies, pipeline bets and growth pressures reshaping ...

Pfizer hasn't yet tapped into the highly lucrative market of diabetes drugs that have been increasingly used for weight loss purposes. Searching for a weight-loss drug but don't like the idea of an ...

Lindsay Tinney, 50, took the Depo-Provera shot for seven years before she came off the injection to try for a baby in 2004.

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

The mother of a woman who died after taking the Depo-Provera injection is now among hundreds of women in the UK seeking legal ...

May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast cancer drug for ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy ...

Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma: New York Thursday, April 30, 2 ...

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...

Windward Bio is in full sail with a $165 million crossover financing to push its long-acting anti-TSLP antibody into phase 3, ...

Rather, industry experts told MD+DI that they expect injectable versions of GLP-1s for weight loss and diabetes will continue ...